Related Experiment Video
Updated: Sep 27, 2026
Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy
Published on: April 3, 2018
Biosafety and product release testing issues relevant to replication-competent oncolytic viruses
1BioReliance, Innovation Park, Stirling, UK. mwisher@bioreliance.com
Abstract:
Replication competent oncolytic viruses, like other biological products, are at risk from contamination by bacteria, fungi, mycoplasma and viruses that must be eliminated from the final product. This article reviews the regulatory guidance for the manufacture and testing for oncolytic virus products. A testing strategy covering the testing of cell lines, virus banks, virus harvests and purified product is described.
Insights
Contamination control is crucial for oncolytic virus products. This review outlines regulatory guidance and a testing strategy for ensuring the safety and purity of these biological therapies throughout manufacturing.
Area of Science:
- Biotechnology
- Virology
- Regulatory Science
Background:
- Replication competent oncolytic viruses are biological products susceptible to microbial and viral contamination.
- Ensuring product purity is essential for the safety and efficacy of oncolytic virus therapies.
- Existing regulatory frameworks guide the manufacturing and testing of biological products.
Purpose of the Study:
- To review regulatory guidance for the manufacture and testing of oncolytic virus products.
- To describe a comprehensive testing strategy for contamination control.
- To ensure the safety and quality of final oncolytic virus products.
Main Methods:
- Review of current regulatory guidelines for biological product manufacturing.
- Development of a multi-stage testing strategy.
- Inclusion of testing protocols for cell lines, virus banks, harvests, and purified products.
Main Results:
- Identification of critical control points for contamination in oncolytic virus production.
- A structured testing approach is proposed to mitigate risks.
- Regulatory compliance is emphasized throughout the manufacturing process.
Conclusions:
- Implementing a robust testing strategy is vital for oncolytic virus safety.
- Adherence to regulatory guidance ensures product quality and patient safety.
- Continuous monitoring and testing are necessary for reliable oncolytic virus therapeutics.
